We are international
Donate
TEXT SIZE   

Investigational Agents

Elotuzumab
Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets SLAMF7, a cell surface glycoprotein highly expressed on myeloma cells and hematopoietic cells but not expressed on nonhematopoietic cells . Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.